Discovery of KT-474a Potent, Selective, and Orally Bioavailable IRAK4 Degrader for the Treatment of Autoimmune Diseases.

Authors: Zheng, Xiaozhang, Ji, Nan, Campbell, Veronica, Slavin, Anthony, Zhu, Xiao, Chen, Dapeng, Rong, Haojing, Enerson, Brad, Mayo, Michele, Sharma, Kirti, Browne, Chris M., Klaus, Christine R., Li, Haoran, Massa, Ginny, McDonald, Alice A., Shi, Yatao, Sintchak, Mike, Skouras, Stephanie, Walther, Dirk M., Yuan, Karen

Source: Journal of Medicinal Chemistry; 10/24/2024, Vol. 67 Issue 20, p18022-18037, 16p

Discovery of KT-413, a Targeted Protein Degrader of IRAK4 and IMiD Substrates Targeting MYD88 Mutant Diffuse Large B‑Cell Lymphoma.

Authors: Weiss, Matthew M., Zheng, Xiaozhang, Ji, Nan, Browne, Chris M., Campbell, Veronica, Chen, Dapeng, Enerson, Brad, Fei, Xue, Huang, Xin, Klaus, Christine R., Li, Haoran, Mayo, Michele, McDonald, Alice A., Paul, Atanu, Rong, Haojing, Sharma, Kirti, Shi, Yatao, Slavin, Anthony, Walther, Dirk M., Yuan, Karen

Source: Journal of Medicinal Chemistry; 7/11/2024, Vol. 67 Issue 13, p10548-10566, 19p

This result is not displayed to guests.
Login for full access.